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Abstract 
Background: Chinese medicine theory shows that “lung being connected with large intestine”, and the modern western 
medicine also shows that the lung and intestinal tract affect each other in physiological and pathological conditions. If 
the lung ventilation dysfunction is caused by inflammatory exudate or secretions obstruction of the small airway 
ventilation, blood gas partial pressure is increased and intestinal gas absorption difficulty may lead to intestinal 
inflation and dysfunction (Wang N et al., 2011). Rheum palmatum L. can play the roles of anti-coagulation and 
anti-thrombosis, and improve microcirculation through lowering the endotoxin-induced permeability of microvascular 
tissue, reducing tissue oedema, decreasing inflammatory exudation and necrosis, and enhancing cyto-protection 
mechanism (Yang TZ et al., 2014). Therefore, systemic evaluation of the evidence pertaining to the usage of Rheum 
palmatum L. in treating acute lung injury and acute respiratory distress syndrome (ARDS)  has significant 
clinical significance.  
Materials and Methods: Various Electronic Databases CBM, CNKI, VIP, Wanfang, PubMed and Cochrane Library 
were searched until December 2015. Numerous randomized-controlled trials (RCTs) evaluating the efficacy of 
Rheum palmatum L. for the treatment of acute lung injury and acute respiratory distress syndrome  were 
collected. The quality of the included studies was evaluated and a meta-analysis was performed using the RevMan5.0 
software.  
Results: Eight RCTs involving 489 patients were selected for this review. The results of the Meta-analysis revealed that 
Rheum palmatum L. therapy, combined with routine comprehensive treatment, was significantly superior to that of 
routine comprehensive treatment alone, in the areas of decreasing mortality, the mechanical ventilation time, the level 
of interleukin-6,8 and the untoward effect, and also in improving arterial blood gas (PaO2/FiO2, PaO2) (P<0.05).  
Conclusion: Compared with treatment with routine comprehensive alone, Rheum palmatum L. treatment combined 
with routine comprehensive, has been shown to effectively decrease the mortality, mechanical ventilation time and 
ameliorate the arterial blood gas, the cytokine levels, and the untoward effect. However, the evidence appears not to be 
very compelling due to the poor quality of the original studies. 
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Introduction 
 
Acute respiratory distress syndrome (ARDS) refers to the acute hypoxic respiratory failure, which is caused by 
alveolar damage induced by inflammatory injury of pulmonary capillary endothelial cells and alveolar epithelial cells 
in the process of severe infection, shock, trauma and burns, and with the pathological physiological characteristics of 
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fewer lung volume, lower lung compliance, serious imbalance of ventilation/blood flow ratio (Bernard et al., 1994). 
According to the ARDS diagnosis standards put forward by the medical conference in Berlin, Germany in October 
2011, a draft definition proposed 3 mutually exclusive categories of ARDS, based on degree of hypoxemia: mild (200 
mm Hg ＜ PaO2/FIO2 ≤ 300 mm Hg), moderate (100 mm Hg ＜ PaO2/FIO2 ≤ 200 mm Hg), and severe (PaO2/FIO2 ≤ 
100 mm Hg), and 4 ancillary variables for severe ARDS: radiographic severity, respiratory system compliance (≤40 
mL/cm H2O), positive end-expiratory pressure (≥10 cm H2O), and corrected expired volume per minute (≥10 L/min) 
(ARDS Definition Task Force, 2012). Overall, it is a dangerous disease with a very poor prognosis and the mortality 
rate can reach as high as 40%-50% [Li et al., 2009]. According to the existing evidence, we can increase the intensity 
of treatment measures in accordance with the severity of ARDS [Liu et al., 2012]. Due to the heterogeneity of ARDS 
disease, however, treatment should be tailored according to the case of each patient. Therefore, in clinical decision 
making, we need to evaluate the benefit and risk of various treatment approaches based on the evidence-based medicine, 
in order to develop individualized treatment plans for each patient and ensure high clinical benefits for all. At present, 
many doctors act according to the theory of the interior-exterior relationship between the lung and the large intestine, 
and adopt a treatment methodology of combining Rheum palmatum L. with the routine comprehensive approach to treat 
ARDS, and procure a certain effect. Up to this day, a systematic evaluation about Rheum palmatum L. combined with 
routine comprehensive therapy for treating ARDS has not been reported. Therefore, it was deemed necessary to 
conduct a systematic review of the method of applying Rheum palmatum L. in combination with the routine 
comprehensive approach to treat ARDS, in order to provide solid scientific reference that would facilitate a reasonable 
individualized treatment plan for ARDS patients. 
 
Methods and Materials 
 
The supporting PRISMA checklist is available as supporting information; see Checklist Fig. S1. 
 
Search strategies and study selection 
 
Literature search was conducted in the National Knowledge Infrastructure (1999-2015), VIP Database for Chinese 
Technical Periodicals (1989-2015), PubMed (1950-2015), Chinese Bio-Medical Literature Database (1990-2015), and 
Cochrane Library (Issue 10 of 12, 2015). All of these searches ended at the end of December 2015. To search the 
databases, we used the terms “Acute respiratory distress syndrome”, “Acute lung injury”, “Western medicine”, 
“Rheum palmatum L. combined with western medicine”, and “TCM combined with Western medicine”. These terms 
were combined variously and used according to the database searched. The bibliographies of the included trials were 
searched for additional references. The data of the included trials were extracted independently by two authors (Y. Liu 
and T. Z. Yang). The extracted data analyzed in this study mainly included paper authors, publication year, study size, 
details of methodological information, drug name and outcome indicators (for example, total effective rate). 
Disagreement between us was resolved by group discussion and reached consensus through a third party (J. X. Chen). 
 
Inclusion Criteria 
 
All the parallel-randomized controlled trials (RCTs) must be based on the principle of participants, interventions, 
comparisons, outcomes and study (PICOS) as follows: P: ARDS patients; I: comprehensive treatment with mechanical 
ventilation and traditional Chinese medicine treatment with Rheum palmatum L.; C: comprehensive treatment with 
mechanical ventilation combined with Rheum palmatum L. vs. comprehensive treatment with mechanical ventilation; O: 
Primary outcomes: mortality, mechanical ventilation time, oxygenation index (PaO2/FiO2), arterial partial pressure of 
oxygen (PaO2) and untoward effect; Secondary outcomes: cytokine levels such as interleukin-6 (IL-6), interleukin-8 
Yang et al., Afr J Tradit Complement Altern Med., (2017) 14 (2): 334-347 
doi:10.21010/ajtcam.v14i2.35 
336 
 
(IL-8). There were no restrictions on age, population characteristics, languages or publication types. 
 
Trial quality assessment  
 
The quality of included trials was evaluated by two authors (Y. Liu and T. Z. Yang) and assessed by using the „risk 
of bias‟ assessment tool according to the „Cochrance Handbook of Systematic Review of Interventions‟ (Chapter 8.5) 
with randomized controlled trials including: sequence generation, allocation concealment, blinding, incomplete 
outcome date, and selective outcome reporting. The quality of all the included trials was divided into 3 categories as 
low, unclear, and high risk of bias. Trials that met all the criteria were classified to low risk of bias, trials met none of 
the criteria were classified to high risk of bias, and other trials with insufficient information acquired to make judgment 
were classified to unclear risk of bias (Figure S2.1 and S2.2).  
 
Data analysis 
 
The data was analyzed by using the statistical package (RevMan 5.0) provided by the Cochrane Collaboration. 
Measurement data were summarized by using Mean Difference (MD) with 95% confidence interval (CI) for continuous 
outcomes. Fixed-effect or random-effect model used in the analysis depended on the absence or presence of 
significance heterogeneity which was evaluated by the Chi-square and I-square (I
2
) tests. Measurement data with the 
same unit were summarized by using weight mean difference (WMD) with 95% CI, and the Measurement data with 
different unit were summarized by using standardized mean difference (SMD) with 95% CI (Altuntas et al., 2006). 
 
Results 
Description of included studies 
 
The flow chart depicts the whole search process and study selection (Figure 1-X). After searching the six 
databases, 140 citations were screened. 54 articles were searched in the CBM database, 19 articles were retrieved from 
VIP, 49 articles were searched in CNKI and 4 articles were retrieved from PubMed. There was no related literature 
retrieved in the Cochrane Library. 83 papers were excluded due to duplicated publication. 22 of them were excluded 
on account of obvious ineligibility, which contained irrelevant titles and abstracts content. 27 articles were excluded by 
reason of non-RCTs, incomplete data, unqualified control, and so on. Finally, 8 RCTs (Ming et al., 2011; Song et al., 
2004; Zhou et al., 2008; Yan et al., 2001; Feng J et al., 2012; Weng et al., 2008; Lu et al., 2009; Cui et al., 2001) were 
included and summarized in Tables 1 and 2.  
A total of 489 participants with ALI/ARDS were involved in these studies, with the average number of 61 per trial, 
ranging from 31 to 100. All the included RCTs in this study were conducted in China and published in Chinese, no one 
published in English. The quality of the included studies was low, but the baseline of the experimental group and 
control group was good (Tables 1 and 2, Figure 2-X and Figure 3-X.). 
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PRISMA 2009 Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1-X. PRISMA 2009 Flow Diagram 
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 Table 1: The basic features of included randomized controlled trials. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study ID 
treatment cycle 
(d) 
N 
(E/C) 
Patient age Comorbidity Cause of ARDS 
Ming et al.2011 5 50/50 43±25 Respiratory failure 
primary diseases: Severe pulmonary infection, necrotic 
pancreatitis, bacterial encephalitis, cholecystitis, peritonitis 
Song et al.2004 7 40/20 46±19 unstated undefined 
Zhou et al.2008 7 40/20 48.9±6.3 unstated 
Trauma, necrotic pancreatitis, infection, suppurative cholangitis, 
DIC, post-renal transplantation 
Yan et al.2001 7-10 16/15 46±12 unstated Severe acute pancreatitis 
Feng et al.2012 7 32/32 48.5±12.3 acute ulcer 
General infection, necrotic pancreatitis, multiple trauma, 
organophosphorus intoxication, after cardiopulmonary 
resuscitation 
Cui et al.2011 Unclear 20/20 44.3 
Mediastinal tumors, esophagus 
cancer, lung cancer 
Thoracic surgery, thoracic trauma 
Weng et al. 2008 6 40/40 45.22±8.14 unstated Thoracoabdominal trauma, maxilla-facial injury 
Lu et al. 2009 7 27/27 48.1±6.8 unstated 
Multiple injuries, chest and abdomen surgery, necrotic 
pancreatitis, organophosphorus intoxication, necrotizing intestinal 
obstruction, severe pneumonia with septic shock 
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Table 2: The basic features of included randomized controlled trials. 
Study ID Treatment measures Outcome Measures 
Experimental group Control group 
Ming et al. 
2011 
0.1g/ml rhubarb decoction nasal feeding by stomach tube every 8 
hours combined with mechanical ventilation 
Mechanical ventilation 
The comparison of baseline, mortality rate, the duration of 
hospitalization in ICU, Pplat, PIP, Mpaw, Raw, PaO 2, 
PaO2/FiO2, PaCO2, pH value, MAP, HR, CO, SVR 
Song et al. 
2004 
0.03～0.06g/ml rhubarb decoction nasal feeding by stomach tube 
every 8 hours combined with mechanical ventilation 
Mechanical ventilation 
The comparison of baseline, PaO2/FiO2, mechanical 
ventilation time, the incidence of pressure ulcers, 
mortality rate 
Zhou et al. 
2008 
0.6g/ml rhubarb decoction nasal feeding by stomach tube every 8 
hours combined with mechanical ventilation  
Mechanical ventilation 
The comparison of baseline, mortality rate, the 
hospitalization time, mechanical ventilation time, PaO2, 
PaO2/FiO2, IL-6, IL-8 
Yan et al. 
2001 
0.1g/ml rhubarb decoction nasal feeding by stomach tube every 
24 hours combined with mechanical ventilation, cure the primary 
disease, improve minicirculation and nutrition support  
Mechanical ventilation, cure the primary 
disease, improve minicirculation and 
nutrition support 
PEEP, the concentration of oxygen, MOF, mortality rate, 
PaO2, SaO2, DO2, Qs/Qt, cardiac output, cardiac index, 
PAPm, PVR 
Feng et al. 
2012 
0.3g/ml rhubarb decoction nasal feeding by stomach tube every 8 
hours combined with mechanical ventilation 
Mechanical ventilation 
The comparison of baseline, PaO2/FiO2, PaO2, mechanical 
ventilation time, mortality rate, IL-6, IL-8, the incidence 
of stress ulcer 
Cui et al. 
2011 
0.03～0.05g/ml rhubarb decoction nasal feeding by stomach tube 
every 8 hours combined with united injury treatment, antibiotic 
treatment, respiratory support and nutrition support  
United injury treatment, antibiotic 
treatment, respiratory support and 
nutrition support 
mortality rate, ventilator treatment time 
Weng et al.  
2008 
0.03g/ml rhubarb decoction nasal feeding by stomach tube every 
8 hours combined with cure the primary disease, mechanical 
ventilation, circulation and respiration supporting, oxygen 
therapy, hemostasis and blood transfusion, and antibiotic therapy   
Mechanical ventilation, circulation and 
respiration supporting, oxygen therapy, 
hemostasis and blood transfusion, and 
antibiotic therapy 
the duration of hospitalization in ICU, the hospitalization 
time, the incidence rate of ARDS, mortality rate, RR, 
PaCO2, PaO2/FiO2, PaO2, TNF-α, IL-6, IL-8, IL-2 
Lu et al.  
2009 
0.3g/ml rhubarb decoction nasal feeding by stomach tube every 8 
hours combined with mechanical ventilation 
Mechanical ventilation 
PaO2/FiO2、PaO2、SaO2、PIP、Raw、CL 
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Figure 2-X: Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages 
across all included studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-X: Risk of bias summary: review authors' judgements about each risk of bias item for each included study. 
 
Comparison of clinical mortality rate 
 
Seven out of eight RCTs (Ming et al., 2011; Song et al., 2004; Zhou et al., 2008; Yan et al., 2001; Feng et al., 
Weng et al., 2012; Cui et al., 2011) reported the comparison of clinical mortality rate between experimental group and 
control treatment group. There is no significant heterogeneity between the studies (I
2
=0%), so we used the fixed effect 
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model for analysis. Meta-analysis results showed a significant difference in the mortality rate between the two 
treatments [RR=0.42, 95%CI (0.30, 0.60), Z=4.81, P<0.00001] (Figure 4-X). The clinical mortality rate of the Rheum 
palmatum L. therapy combined with routine comprehensive in the treatment of ARDS was lower than the routine 
comprehensive approach alone. 
 
 
 
 
 
 
 
 
 
 
Figure 4-X. The forest plot of mortality rate 
 
Comparison of mechanical ventilation time 
 
3 trials [Song XQ et al., Zhou XT et al., Feng J et al.] made a comparison of the therapeutic effects on 
mechanical ventilation time. There were 184 patients, 112 cases in the Rheum palmatum L. group and 72 cases in the 
control group. Meta-analysis results showed a significant difference in reducing the mechanical ventilation time of 
patients [MD=-13.27, 95%CI (-18.08, -8.46), Z=5.41, P<0.00001] (Figure 5-X). More specifically, the therapeutic 
efficacy of Rheum palmatum L. combined with routine comprehensive therapy was superior to that of routine 
comprehensive approach alone, in reducing the mechanical ventilation time of ARDS patients. 
 
 
 
 
 
 
 
 
 
Figure 5-X. The forest plot of mechanical ventilation time 
 
Comparison of arterial blood gas  
 
PaO2 : 5 trials (Ming et al., 2011; Zhou et al., 2008; Yan et al., 2001; Feng et al., 2012; Weng et al., 2008) made a 
comparison of two kinds of treatment on improving the PaO2 levels of patients with ALI/ARDS. A total of 335 patients 
were involved, 178 cases in the experimental group and 157 cases in the control group. There was significant statistical 
heterogeneity in the researches (P=0.0001, I
2
=83%). The results of meta-analysis showed that between the two 
different treatments, there was a significant difference in the level of PaO2 [MD=8.44, 95%CI (4.22, 12.66), Z=3.92, 
P<0.0001] (Figure 6-X). The diamond on the right side of the invalid line, points out that the treatment of Rheum 
palmatum L. combined with routine comprehensive therapy was better than the routine comprehensive approach alone 
in promoting the level of PaO2. 
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Figure 6-X: The forest plot of PaO2 
 
PaO2/FiO2: 5 out of 8 RCTs (Ming et al., 2011; Song et al., 2004; Zhou et al., 2008; Feng et al., 2012; Weng et al., 
2008) made a comparison of the effects of the two kinds of treatment in patients with PaO2/FiO2. There were 364 
patients included in the study of oxygenation index, and the number of patients in the control group and the 
experimental group were 162 and 202, respectively. There is statistical heterogeneity in the researches (P<0.000001，
I
2
=99%). According to meta-analysis, the results indicated that the treatment strategy using Rheum palmatum L. 
combined with routine comprehensive approach was superior to routine comprehensive therapy alone in improving the 
level of PaO2/FiO2 with ALI/ARDS patients [MD=76.12, 95%CI (34.92, 117.33), Z=3.62, P=0.0003] (Figure 7-X). 
 
 
 
 
 
 
 
 
 
Figure 7-X: The forest plot of PaO2/FiO2 
 
Comparison of cytokine levels (IL-6 and IL-8) 
 
Three (Zhou et al., 2008; Feng et al., 2012; Weng et al., 2008) out of eight trials made simultaneous comparison of 
the effect of the two therapeutic modalities in ameliorating the levels of IL-6 and IL-8 with ALI/ARDS patients. There 
was no significant heterogeneity between the studies, IL-6 (P<0.0001，I2=91%), IL-8 (P=0.99，I2=0%). Meta-analysis 
results indicated that in lowering the level of IL-6 in patients with ARDS, the curative effect of experimental group was 
significantly better than that of the control group, and with statistically significant difference between the two groups 
[MD=-7.44, 95%CI (-12.48, -2.41), Z=2.90, P=0.004] (Figure 8-X). At the same time, when comparing the efficacy of 
the two therapeutic methods in reducing the levels of cytokines in patients with IL-8, the therapeutic effect of Rheum 
palmatum L. combined with routine comprehensive treatment remained significantly superior to that of routine 
comprehensive approach alone, and the difference was also statistically significant [MD=-7.7, 95%CI (-9.36, -6.04), 
Z=9.08, P<0.00001] (Figure 9-X). 
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Figure 8-X. The forest plot of IL-6 
 
 
 
 
 
 
 
 
Figure 9-X. The forest plot of IL-8  
Untoward reaction 
Two papers (Song et al., 2004; Feng et al., 2012) reported the incidence of stress ulcer after either therapeutic option. In 
total, there were 124 patients, with 72 cases belonging to the experimental group, and 52 cases in the control group. 
There was no significant heterogeneity between the studies (P=0.87，I2=0%), so the fixed effect model was adopted to 
analyse the outcomes. The results have shown that the incidence of stress ulcer with the experimental group was 
significantly lower than that of control group, and with statistically significant difference [RR=0.58, 95%CI (0.38, 0.89), 
Z=2.49, P=0.01] (Figure 10-X).  
  
 
 
 
 
 
 
Figure 10-X: The forest plot of the incidence of stress ulcer  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11-X. The funnel plot 
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Publication bias 
 
Seven trials compared the effect of the two therapeutic modalities in ameliorating the clinical mortality rates in 
ARDS patients. A funnel plot analysis showed a serious asymmetry in the general effective rate among the 7 trials 
(Figure 11-X). It indicated that the included literatures suffer from low quality and publication bias. Because of the 
limited number of papers, the result of this systematic review is deemed useful only for reference. 
 
 
Discussion 
 
There are more than 100 kinds of etiologic factors for ARDS. The various factors inducing ARDS differ in their 
pathological process and prognosis, and, therefore, the causes are divided into two main categories: direct lung injury 
and indirect lung injury. The former mainly includes severe pulmonary infection, aspiration, pulmonary contusion, 
drowning, pulmonary embolism and oxygen poisoning. The latter mainly involves severe sepsis and septic shock, 
severe non-pulmonary trauma, acute fatal pancreatitis, large area burns, and so on. The most common causes for ARDS 
are severe infection, shock, trauma and burn (He et al., 2011). Although the etiology of ARDS is complex, its 
pathogenesis is also not yet fully elucidated. However, it has been demonstrated that the common “central link” of the 
pathogenesis is the inflammatory process mediated by inflammatory mediators released by a variety of effector cells 
(Gu et al., 2007). In recent years, the role of inflammation mediators, especially the cytokines, has been gathering more 
attention for explaining the pathogenesis of ARDS. 
Traditional Chinese Medicine believes that ARDS belongs to the pathology of “syndrome characterized by 
dyspnea”, “sudden attack of wheezing and dyspnea” and “collapse syndrome caused by dyspnea”. Severe pulmonary 
contusion leads to stagnancy of qi and blood, and impaired dispersion of the lung qi, and thus disturbing the 
physiological conditions of “the interior-exterior relationship of the lung and the large intestine”. If the functional 
activities of the stomach and intestines qi are obstructed, the lung-qi becomes aggravated. Rheum palmatum L. has the 
effect of restoring normal bowel movement, clearing away heat and toxic materials, cooling the blood, and dissipating 
blood stasis. The “Shen Nong Ben Cao” states: “Rheum palmatum L. can clear the stomach and intestines, capture and 
purge fire, clear away heat and toxic materials, engender the new through the old and stabilize the five internal organs”. 
Modern research confirms that Rheum palmatum L. can prevent the membrane flow of calcium ions, influence the 
content of the intracellular calcium and reduce the synthesis and release of inflammatory mediators (Hachida et al., 
1998). Rheum palmatum L. can prevent neutrophil activation by inhibiting the production and release of TNF-α, IL-2, 
IL-6, IL-8 and other cytokines. It could effectively prevent the amplification of inflammatory mediators and the playing 
of biological effects. Rheum palmatum L. also can increase the intestinal peristalsis, relieve constipation by purgation, 
inhibit the translocation of intestinal bacterial and the absorption of endotoxin, and maintain the barrier function of 
intestines and stomach. These can prevent bacteria entering into the blood circulation, reduce endotoxemia, and 
eventually decrease the inflammation of lung tissue (Zhu et al., 2004). In recent years, Rheum palmatum L. is applied to 
salvage many kinds of severe cases, such as among other various types of shock, major multiple injuries, acute 
respiratory distress syndrome and multiple organ dysfunction syndrome (He et al., 2007). 
Based on this paper and meta-analyses of outcomes on mortality, mechanical ventilation time, oxygenation index 
(PaO2/FiO2), arterial partial pressure of oxygen (PaO2), untoward effect, cytokine levels such as interleukin-6 (IL-6), 
interleukin-8 (IL-8), Rheum palmatum L. combined with routine comprehensive therapy may have certain effect on 
patients with ARDS, and the curative effect is superior to routine comprehensive alone in the areas of reducing the 
clinical mortality rate, shortening the mechanical ventilation time and ameliorating the arterial blood gas and cytokine 
levels in patients with ARDS to some extent. According to the two trials, Rheum palmatum L. combined with routine 
comprehensive therapy has less adverse events, compared to routine comprehensive alone with significant difference, 
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and this shows that the safety of Rheum palmatum L. combined with routine comprehensive therapy is better than 
routine comprehensive therapy alone, to some extent. We also considered some limitations of this article before 
accepting the findings. Firstly, the obtained literatures of RCTs in treating ARDS by using Rheum palmatum L. 
combined with routine comprehensive therapy were originally published in Chinese, and no English translation exists. 
Secondly the methodologies of these clinical trials were generally of very poor quality, according to the quality 
assessment tool for quantitative studies, and it also indicated that there is unclear risk of bias in most of trials. The 
methods of randomization and allocation concealment in those trials were described inadequately or incompletely. Most 
randomized studies did not follow the established rules. For example, none of the included 8 trials mentioned any 
single blind without providing detailed information, and we understood that it was difficult to perform double-blinding 
or single-binding because of the peculiarity of ARDS and certain features associated with Chinese herbs, for example, 
aroma and appearance, while it could be feasible that binding to outcome assessor and data analyzer. None of the trials 
explained the concrete method of randomization, and the rest merely provided insufficient information for judging 
whether or not it was conducted properly. The lack of dropout or withdrawal and insufficient side-effect reports were 
some of the factors that negatively impacted the reliability of this review. Thirdly, there was lack of placebo control in 
the included RCTs. One trail claimed that they used placebo control. However, the placebo of these trial is ulinastatin 
(Weng et al., 2008), not Chinese herbs, and it is not an appropriate control for the estimation of the effect of Chinese 
herbs. Therefore, it should be made with caution, when interpreting the positive outcomes of treatment with Chinese 
medicine. To remedy this situation, we suggest using caution when referencing these studies in the future. 
The quality of the clinical research methodology of using Rheum palmatum L. combined with routine 
comprehensive therapy in the treatment of ARDS should be improved. In addition, the following aspects should be 
emphasized. Firstly, the production of random allocation sequences and the hidden random schemes should be reported 
in detail. Secondly, double blind method and placebo control should be applied. Thirdly, the withdrawal and drop-out 
rate should be clearly described. Fourthly, the importance of clinical outcome in a long-term follow-up should be 
reported. The effect of the treatment of the ARDS with Rheum palmatum L. combined with routine comprehensive 
therapy should be improved by designing strict double blind, randomized, controlled trials.  
We hope that future clinical research would be sufficiently designed to avoid the limitations of current research 
methodologies. A revised design should pay particular attention to the use of the final therapeutic effect index, which in 
the cases we examined was highly objective, and thus allow international recognition that would facilitate future 
exchanges. 
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